The fears of a “growth pit” that drove ALXN into the 90s in May 2017 have been proven unwarranted. Expanding indications for Soliris and the introduction of ALXN1210 will drive revenue, widen margins and may keep competitors in the US at bay for another decade. ALXN's recent price action is ...
Read More
Read More
Comments
Post a Comment